Clinical data | |
---|---|
Other names | TZV, Triazavirin |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.217.074 |
Chemical and physical data | |
Formula | C5H4N6O3S |
Molar mass | 228.19 g·mol−1 |
3D model (JSmol) | |
| |
|
Riamilovir is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical.[1] It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.[2]
The principal action of triazavirin is to inhibit the synthesis of viral ribonucleic acid (RNA) and the replication of viral genomic fragments through its synthetic analogue to the bases of purine nucleosides.[3][4][5]
pmid20194696
was invoked but never defined (see the help page).pmid25051708
was invoked but never defined (see the help page).pmid19275052
was invoked but never defined (see the help page).